Literature DB >> 21862226

Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome.

Scott S Hall1, Amy A Lightbody, Brigid E McCarthy, Karen J Parker, Allan L Reiss.   

Abstract

Fragile X syndrome (FXS) is a rare inherited genetic disorder causing severe intellectual disability and autistic-like symptoms. Individuals with FXS, males in particular, often exhibit extreme eye gaze avoidance and hyperarousal when they encounter stressful social situations. We investigated whether oxytocin (OT), a hormone with prosocial and anxiolytic effects, could alleviate symptoms of social anxiety in this population. A randomized double-blind placebo-controlled single-dose trial was performed with intranasal administration of placebo, 24 IU OT and 48 IU OT. Measures of eye gaze frequency, heart rate, respiratory sinus arrhythmia (RSA), heart rate variability (HRV) and salivary cortisol were obtained during a structured social challenge conducted 50 min following OT administration. Ten low-functioning males with FXS (aged 13-28 years) traveled to Stanford for the initial visit: 8 completed the study. Eye gaze frequency improved significantly in response to the 24 IU OT dose and salivary cortisol levels decreased significantly in response to the 48 IU OT dose. There was no effect of OT on heart rate, RSA or HRV although individual plots of the heart rate data suggested that OT increased heart rate in some participants and decreased heart rate in others. These findings suggest that intranasal administration of OT may ameliorate some symptoms of social anxiety in patients with FXS. Further double-blind placebo-controlled studies of OT, conducted in combination with behavioral treatment programs, may be warranted. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862226      PMCID: PMC3353652          DOI: 10.1016/j.psyneuen.2011.07.020

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  53 in total

Review 1.  Moving molecules: mRNA trafficking in Mammalian oligodendrocytes and neurons.

Authors:  Ross Smith
Journal:  Neuroscientist       Date:  2004-12       Impact factor: 7.519

2.  Intranasal oxytocin in obsessive-compulsive disorder.

Authors:  C N Epperson; C J McDougle; L H Price
Journal:  Biol Psychiatry       Date:  1996-09-15       Impact factor: 13.382

Review 3.  Transcription, translation and fragile X syndrome.

Authors:  Kathryn Garber; Karen T Smith; Danny Reines; Stephen T Warren
Journal:  Curr Opin Genet Dev       Date:  2006-05-02       Impact factor: 5.578

4.  Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report.

Authors:  L J Miller; D N McIntosh; J McGrath; V Shyu; M Lampe; A K Taylor; F Tassone; K Neitzel; T Stackhouse; R J Hagerman
Journal:  Am J Med Genet       Date:  1999-04-02

5.  Oxytocin modulates neural circuitry for social cognition and fear in humans.

Authors:  Peter Kirsch; Christine Esslinger; Qiang Chen; Daniela Mier; Stefanie Lis; Sarina Siddhanti; Harald Gruppe; Venkata S Mattay; Bernd Gallhofer; Andreas Meyer-Lindenberg
Journal:  J Neurosci       Date:  2005-12-07       Impact factor: 6.167

6.  Oxytocin increases trust in humans.

Authors:  Michael Kosfeld; Markus Heinrichs; Paul J Zak; Urs Fischbacher; Ernst Fehr
Journal:  Nature       Date:  2005-06-02       Impact factor: 49.962

7.  Fragile X mental retardation protein levels increase following complex environment exposure in rat brain regions undergoing active synaptogenesis.

Authors:  Scott A Irwin; Chariya A Christmon; Aaron W Grossman; Roberto Galvez; Soong Ho Kim; Brian J DeGrush; Ivan Jeanne Weiler; William T Greenough
Journal:  Neurobiol Learn Mem       Date:  2005-05       Impact factor: 2.877

8.  Modeling cortisol rhythms in a population-based study.

Authors:  Nalini Ranjit; Elizabeth A Young; Trivellore E Raghunathan; George A Kaplan
Journal:  Psychoneuroendocrinology       Date:  2005-08       Impact factor: 4.905

9.  Intranasal oxytocin administration attenuates the ACTH stress response in monkeys.

Authors:  Karen J Parker; Christine L Buckmaster; Alan F Schatzberg; David M Lyons
Journal:  Psychoneuroendocrinology       Date:  2005-10       Impact factor: 4.905

10.  Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.

Authors:  D C Crawford; K L Meadows; J L Newman; L F Taft; D L Pettay; L B Gold; S J Hersey; E F Hinkle; M L Stanfield; P Holmgreen; M Yeargin-Allsopp; C Boyle; S L Sherman
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

View more
  53 in total

1.  A 'learning platform' approach to outcome measurement in fragile X syndrome: a preliminary psychometric study.

Authors:  S S Hall; J L Hammond; M Hirt; A L Reiss
Journal:  J Intellect Disabil Res       Date:  2012-04-25

2.  Within vs. between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions.

Authors:  Xu Chen; Pritam Gautam; Ebrahim Haroon; James K Rilling
Journal:  Psychoneuroendocrinology       Date:  2017-01-16       Impact factor: 4.905

3.  Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and women.

Authors:  Xu Chen; Patrick D Hackett; Ashley C DeMarco; Chunliang Feng; Sabrina Stair; Ebrahim Haroon; Beate Ditzen; Giuseppe Pagnoni; James K Rilling
Journal:  Brain Imaging Behav       Date:  2016-06       Impact factor: 3.978

Review 4.  Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Authors:  Ellen R Bradley; Joshua D Woolley
Journal:  Neurosci Biobehav Rev       Date:  2017-05-12       Impact factor: 8.989

5.  TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.

Authors:  C Kağan Gürkan; Randi J Hagerman
Journal:  Res Autism Spectr Disord       Date:  2012-10-01

6.  Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder.

Authors:  Elizabeth A Hoge; Elizabeth A Lawson; Christina A Metcalf; Aparna Keshaviah; Paul J Zak; Mark H Pollack; Naomi M Simon
Journal:  Depress Anxiety       Date:  2012-07-17       Impact factor: 6.505

Review 7.  Oxytocin and Anxiety Disorders: Translational and Therapeutic Aspects.

Authors:  Wadih Jean Naja; Michaelangelo Pietro Aoun
Journal:  Curr Psychiatry Rep       Date:  2017-08-15       Impact factor: 5.285

8.  Outcome measures for clinical trials in fragile X syndrome.

Authors:  Elizabeth Berry-Kravis; David Hessl; Leonard Abbeduto; Allan L Reiss; Andrea Beckel-Mitchener; Tiina K Urv
Journal:  J Dev Behav Pediatr       Date:  2013-09       Impact factor: 2.225

Review 9.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

10.  Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles.

Authors:  Karen L Bales; Allison M Perkeybile; Olivia G Conley; Meredith H Lee; Caleigh D Guoynes; Griffin M Downing; Catherine R Yun; Marjorie Solomon; Suma Jacob; Sally P Mendoza
Journal:  Biol Psychiatry       Date:  2012-10-16       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.